talactoferrin alfa profile

talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5619
CHEMBL ID	290543
CHEBI ID	103981
SCHEMBL ID	332192
MeSH ID	M0504489

Synonym
BRD-A12822115-003-01-6
L000607
CHEBI:103981
talactoferrin alfa
bdbm86547
cas_135349
nsc_135349
SCHEMBL332192
2-(3,4-dichlorophenyl)-n-methyl-n-[2-(1-pyrrolidinyl)cyclohexyl]acetamide
Q27181219
3,4-dichloro-n-methyl-n-[2-(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide
CHEMBL290543
149341-39-9
3,4-dichloro-n-methyl-n-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide
DTXSID101155047

Excerpt	Reference	Relevance
"Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). "	( Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Barlesi, F; Chang, A; Crawford, J; Douillard, JY; Giaccone, G; Malik, R; Manegold, C; Owonikoko, T; Perez-Soler, R; Pultar, P; Ramalingam, S; Thatcher, N; Wang, Y; Zhu, J, 2013)	3.28
"Talactoferrin alfa (TLF) is a unique recombinant form of human lactoferrin. "	( Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Bhattacharya, N; Blenman, KR; Engleman, E; Hwang, G; Lee, PP; Malik, R; Neal, JW; Pultar, P; Riess, JW; San-Pedro Salcedo, M; Wakelee, HA, 2014)	2.16
"Talactoferrin alfa (TLf) is a recombinant human Lf shown to protect against sepsis and necrotizing enterocolitis as well as cancer."	( Comparison of bioactivities of talactoferrin and lactoferrins from human and bovine milk. Du, X; Jiang, R; Lönnerdal, B, 2014)	1.12
"Talactoferrin alfa is a recombinant form of the human glycoprotein, lactoferrin, which has been shown to have a wide range of effects on the immune system. "	( Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial. Dellinger, RP; Guntupalli, K; Levy, MM; Malik, R; Marshall, JC; Simonson, SG; Singer, M; Vincent, JL, 2015)	1.86

Excerpt	Reference	Relevance
"TLF, in combination with C/P, demonstrated an apparent improvement in RR, PFS, and OS in patients with previously untreated stage IIIB/IV non-small cell lung cancer and appears to enhance activity without significant additional toxicity."	( A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. Advani, SH; Bapna, A; Digumarti, R; Doval, DC; Julka, PK; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Raman, G; Ranade, AA; Varadhachary, A; Wang, Y, 2011)	0.37

Excerpt	Relevance	Reference
" Oral TLF or placebo was administered for a maximum of three 14-week cycles with dosing for 12 consecutive weeks followed by 2 weeks off."	( Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. Advani, SH; Bapna, A; Digumarti, R; Ismail, PM; Madhavan, J; Malik, R; Nag, S; Parikh, PM; Patil, S; Sekhon, JS; Vaid, A; Varadhachary, A; Wang, Y; Zhu, J, 2011)	0.37
"Male rats were orally dosed with vehicle or talactoferrin (1000 mg/kg, every day) for 5 d before being subjected to T/HS or trauma-sham shock (T/SS)."	( Oral pretreatment with recombinant human lactoferrin limits trauma-hemorrhagic shock-induced gut injury and the biological activity of mesenteric lymph. Chandler, B; Deitch, EA; Feketova, E; Qin, Y; Quackenbush, EJ; Son, JY, 2014)	0.4
"These results provide a proof of principle that prophylactic dosing of oral talactoferrin can potentially protect the gut in a T/HS model and limit the production of biologically active factors in rat gastrointestinal tissue subjected to ischemia-reperfusion-type injuries."	( Oral pretreatment with recombinant human lactoferrin limits trauma-hemorrhagic shock-induced gut injury and the biological activity of mesenteric lymph. Chandler, B; Deitch, EA; Feketova, E; Qin, Y; Quackenbush, EJ; Son, JY, 2014)	0.4

Class	Description
acetamides	Compounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	8 (36.36)	29.6817
2010's	14 (63.64)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (43.48%)	5.53%
Reviews	3 (13.04%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (43.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis [NCT00630656]	Phase 2	190 participants (Actual)	Interventional	2008-04-30	Completed
An Open Label Pilot Study to Evaluate the Effect on the Immune System of Talactoferrin in Adults With Non-Small Cell Lung Cancer (NSCLC) [NCT00923741]	Phase 1	10 participants (Actual)	Interventional	2008-06-19	Completed
Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants [NCT00854633]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2009-06-30	Recruiting
FORTIS-C: A Phase 3, Randomized, Placebo-controlled Study of Oral Talactoferrin in Combination With Carboplatin and Paclitaxel as First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer [NCT00706862]	Phase 3	1,100 participants (Anticipated)	Interventional	2009-02-28	Recruiting
A Phase Ib Immunomodulatory Study of Single Agent Talactoferrin in Patients With Select Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC) and Squamous Head and Neck Cancer (HNSCC) [NCT01528137]	Phase 1	4 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to Negative data from another trial led to termination of this trial by sponsor.)
FORTIS-M: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens [NCT00707304]	Phase 3	742 participants (Actual)	Interventional	2008-11-30	Completed
OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis [NCT01273779]	Phase 2/Phase 3	1,280 participants (Anticipated)	Interventional	2011-06-30	Suspended(stopped due to Data Safety Monitoring Board recommendation)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.96	2	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
carboplatin [no description available]	4.96	2	1
lactoferrin Lactoferrin: An iron-binding protein that was originally characterized as a milk protein. It is widely distributed in secretory fluids and is found in the neutrophilic granules of LEUKOCYTES. The N-terminal part of lactoferrin possesses a serine protease which functions to inactivate the TYPE III SECRETION SYSTEM used by bacteria to export virulence proteins for host cell invasion.	11.59	22	10

Condition	Relationship Strength	Studies	Trials
Blood Poisoning [description not available]	7.02	4	3
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	7.02	4	3
Carcinoma, Non-Small Cell Lung [description not available]	8.04	10	4
Cancer of Lung [description not available]	7.68	9	3
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	8.04	10	4
Lung Neoplasms Tumors or cancer of the LUNG.	7.68	9	3
Hemorrhagic Shock [description not available]	2.1	1	0
Injuries Used with anatomic headings, animals, and sports for wounds and injuries. Excludes cell damage, for which pathology is used.	2.1	1	0
Injury, Ischemia-Reperfusion [description not available]	2.1	1	0
Wounds and Injuries Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity.	2.1	1	0
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.1	1	0
Local Neoplasm Recurrence [description not available]	2.1	1	0
Necrotizing Enterocolitis [description not available]	4.82	2	1
Cancer of Colon [description not available]	2.1	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.1	1	0
Enterocolitis, Necrotizing ENTEROCOLITIS with extensive ulceration (ULCER) and NECROSIS. It is observed primarily in LOW BIRTH WEIGHT INFANT.	4.82	2	1
Endotoxin Shock [description not available]	4.41	1	1
Shock, Septic Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.	4.41	1	1
Infant, Premature, Diseases Diseases that occur in PREMATURE INFANTS.	4.43	1	1
Health Care Associated Infection [description not available]	4.43	1	1
Pachymeningitis [description not available]	4.43	1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	4.43	1	1
Bacterial Infections, Gram-Negative [description not available]	4.43	1	1
Bacterial Infections, Gram-Positive [description not available]	4.43	1	1
Cross Infection Any infection which a patient contracts in a health-care institution.	4.43	1	1
Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)	4.43	1	1
Pneumonia Infection of the lung often accompanied by inflammation.	4.43	1	1
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	4.43	1	1
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	4.43	1	1
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	4.43	1	1
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	4.43	1	1
Injuries, Soft Tissue [description not available]	2.04	1	0
Complications of Diabetes Mellitus [description not available]	2.04	1	0
Adenocarcinoma Of Kidney [description not available]	4.4	2	2
Cancer of Kidney [description not available]	4.4	2	2
Metastase [description not available]	4.4	2	2
Benign Neoplasms [description not available]	4.68	3	2
Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.	4.4	2	2
Kidney Neoplasms Tumors or cancers of the KIDNEY.	4.4	2	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	4.4	2	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	4.68	3	2
Disease Exacerbation [description not available]	3.45	1	1
Diabetic Feet [description not available]	3.42	1	1
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	3.42	1	1
Adenocarcinoma, Basal Cell [description not available]	2.03	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.03	1	0

talactoferrin alfa

Description

Cross-References

Synonyms (15)

Research Excerpts

Overview

Compound-Compound Interactions

Dosage Studied

Drug Classes (1)

Research

Studies (22)

Market Indicators

Research Demand Index: 13.62

Study Types

Clinical Trials (7)

Trial Overview

talactoferrin alfa

Description

Cross-References

Synonyms (15)

Research Excerpts

Overview

Compound-Compound Interactions

Dosage Studied

Drug Classes (1)

Research

Studies (22)

Market Indicators

Research Demand Index: 13.62

Study Types

Clinical Trials (7)

Trial Overview

Related Drugs (3)

Related Conditions (46)